Pfizer

Pfizer has submitted data on its bivalent COVID-19 booster shot that specifically targets the latest omicron subvariants. If authorized, the company says the shots could be ready as soon as September.

In the U.S., more than 1 out of 5 residents is fully vaccinated against COVID-19. But elsewhere in the world, vaccination rates are much lower. Some poor nations have yet to receive a single dose.

Pfizer says it will submit the clinical trial results "as soon as possible" to the U.S. Food and Drug Administration, and is hoping to start vaccinating children before the next school year.

WMFE health reporter Abe Aboraya joins Intersection to talk about the science, logistics and the PR campaign behind the massive vaccination effort getting underway.